Trial reportEuropean journal of applied physiology and occupational physiology1994
Effects of 2-chloropropionate on venous plasma lactate concentration and anaerobic power during periods of incremental intensive exercise in humans.
Trial report in European journal of applied physiology and occupational physiology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Lactate uptake by forearm skeletal muscles during repeated periods of short-term intense leg exercise in humans.European journal of applied physiology and occupational physiology · 1996Trial
- Aerobic and anaerobic contribution to Wingate test performance in sprint and middle-distance runners.European journal of applied physiology and occupational physiology · 1995Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the effects of a stimulation of pyruvate dehydrogenase (PDH) activity induced by 2-chloropropionate (2-CP) on venous plasma lactate concentration and peak anaerobic power (W an, peak) during periods (6 s) of incremental intense exercise, i.e. a force-velocity (F-v) test known to induce a marked accumulation of lactate in the blood. The F-v test was performed twice by six subjects according to a double-blind randomized crossover protocol: once with placebo and once with 2-CP (43 mg.kg-1 body mass). Blood samples were taken at ingestion of the drug, at 10, 20, and 40 min into the pretest period, at the end of each period of intense exercise, at the end of each 5-min recovery period, and after completion of the F-v test at 5, 10, 15, and 30 min. During the F-v test, venous plasma lactate concentrations with both placebo and 2-CP increased significantly when measured at the end of each period of intense exercise (F = 33.5, P < 0.001), and each 5-min recovery period (F = 24.6, P < 0.001). Venous plasma lactate concentrations were significantly lower with 2-CP at the end of each recovery period (P < 0.01), especially for high braking forces, i.e. 8 kg (P < 0.05), 9 kg (P < 0.02), and maximal braking force (P < 0.05). After completion of the F-v test, venous plasma lactate concentrations were also significantly lower with 2-CP (P < 0.001). The percentage of lactate decrease between 5- and 30-min recovery was significantly higher with 2-CP than with the placebo [59 (SEM 4)% vs 44.6 (SEM 5.5)%, P < 0.05]. Furthermore, W an, peak was significantly higher with 2-CP than with the placebo [1016 (SEM 60) W vs 957 (SEM 55) W, P < 0.05]. In conclusion, PDH activation by 2-CP attenuated the increase in venous plasma lactate concentration during the F-v test. Ingestion of 2-CP led to an increased W an, peak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.